Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status

ALK inhibitors are promising for treating ALK rearrangement non-small-cell lung cancer (NSCLC), but secondary mutations of ALK can sometimes inhibit their effectiveness. A 54-year-old woman with lung adenocarcinoma harboring ALK rearrangement previously treated with first-line alectinib and second-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitadai, Rui, Okuma, Yusuke, Kawai, Shoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301300/
https://www.ncbi.nlm.nih.gov/pubmed/30588026
http://dx.doi.org/10.2147/OTT.S186213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301300/
https://www.ncbi.nlm.nih.gov/pubmed/30588026
http://dx.doi.org/10.2147/OTT.S186213

Ejemplares similares